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Objectives: This study was initiated to determine the local profile of bloodstream 
infections (BSIs) in patients with hematological malignancies. Particular attention was 
given to the characteristics of BSIs associated with death.
Patients and Methods: 255 patients hospitalized in the adult hematology ward of 
Yamagata University Hospital for chemotherapy from January 2003 to December 2007 
were studied retrospectively, and BSIs were identified. To examine the characteristics of 
BSIs associated with death, BSIs with onset within 21 days prior to patients' death were 
defined as critical BSIs and compared to non-critical BSIs.
Results: A total of 119 BSIs were identified in 67 of 255 patients. Of 119 BSIs, 29 
(24.3%) could be classified as critical BSIs. On logistic regression analysis, profound 
neutropenia (ANC=0 cels/μL) (OR=19.9; 95% CI=3.6 to 109.4; P<0.01) was the 
independent factor most associated with BSI onset. And Performance status 4 of the 
Eastern Cooperative Oncology Group criteria (bedridden status) (OR=20.1; 95% CI=4.4 
to 91.0; P<0.01) was the independent factor most associated with critical BSI episodes. 
On univariate analysis, pneumonia and gastrointestinal disturbance were associated 
with critical BSI episodes. The pathogens were markedly diferent between critical and 
non-critical BSIs. The most common pathogens in critical BSIs were Enterococcus 
species (11 of 29; 37.9%), whereas Staphylococcus species were most common in non-
critical BSIs (42 of 90; 46.7%).
Conclusion: We determined the local profile of BSIs, and these data are useful for risk-
based, empirical choosing of antimicrobial therapy in our ward. BSIs associated with 
death occur in patients with severe underlying conditions, so that non-antimicrobial 
supportive therapy needs to be implemented to improve BSI patients' survival.
Key words : bloodstream infection, hematological malignancy, neutropenia
ABSTRACT
　Address for Correspondence：Katsushi Tajima, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan
－40－
Yamamoto, Shiono, Suzuki, Kouno, Hiroshima, Kato, Tajima, Kato
INTRODUCTION
　In spite of the development of antimicrobial 
therapy, bloodstream infection (BSI) is a major 
cause of death in patients with hematological 
malignancies1), 2). In the 1960s, the relationship 
between neutropenia and infection was first 
recognized, and the mortality rate in neutro-
penic patients with leukemia and Gram-
negative infections was 91%3). The introduc-
tion of empirical antimicrobial therapy altered 
the management of febrile neutropenia4). Since 
then, the outcomes of febrile neutropenia have 
improved with the choice of more efective, less 
toxic, broad-spectrum antibiotics. In the adult 
hematology ward of Yamagata University 
Hospital, empirical antimicrobial therapy choi-
ces have been made according to the guidelines 
published by the Infectious Diseases Society of 
America (IDSA)5).
　The use of antimicrobial prophylaxis in 
neutropenic patients remains controversial. 
The problems of prophylaxis are the lack of 
survival benefits and the risk of inducing 
antimicrobial resistance6). However, the bene-
fits of antimicrobial prophylaxis have been 
emphasized by two major double-blind, 
placebo-controled trials with levofloxacin, 
which showed very significant reductions in al 
infection-related events7), 8). In our ward, 
antimicrobial prophylaxis has been given to 
patients with dose-intensity chemotherapy, 
such as remission-induction therapy for acute 
leukemia, salvage therapy for malignant 
lymphoma, and conditioning regimens for 
hematopoietic  stem  cel  transplantation 
(HSCT), and moderately myelosuppressive 
chemotherapy, such as the CHOP regimen for 
lymphoma. However, in the face of emerging 
multidrug-resistant organisms and the dy-
namic epidemiology of pathogens, empirical 
and prophylactic antimicrobial therapies have 
become increasingly dificult for the patients 
with hematological malignancies, who are 
highly compromised patients. Hence, the aim 
of this study was to determine the local profile 
of BSIs; in order to improve the outcome of 
BSI patients, particular attention was given to 
the characteristics of BSIs associated with 
death.
MATERIALS AND METHODS
　Setting: This study was conducted in the 
adult hematology ward of Yamagata University 
Hospital. Approximately 120 patients with 
hematological malignancies are admitted to 
this ward annualy; half of them are newly 
diagnosed. The ward has 20 to 30 beds with 3 
clean rooms.
　Study design and patients: Al hospitalized 
patients with hematological malignancies 
between January 1, 2003, and December 31, 
2007 were included in this study. The medical 
records and computerized microbiology labora-
tory records were searched to identify BSIs in 
these patients. Patients with a history of BSIs 
were selected as BSI patients. A BSI with its 
onset within 21 days before the patient's death 
was classified as a critical BSI and considered 
to be associated with the patient's death, 
regardless of the underlying disease status9).
　Definitions: The folowing terms were 
defined prior to data analysis. A BSI was 
defined as bacteremia and fungemia docu-
mented by detection of at least one specimen in 
a blood culture from a patient with a systemic 
inflammatory response syndrome (e.g., fever, 
tachycardia, tachypnea, or leukocytosis); when 
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the isolate was a potential skin contaminant 
(such  as  coagulase-negative  staphylococci 
[CoNS],  a  Bacilus,  or  Corynebacterium 
species), to confirm the BSI, the two folowing 
criteria had to be met: (A) the presence of an 
intravascular catheter; and (B) the initiation of 
anti-microbial therapy1), 9), 10). Sequential blood 
cultures yielding the same pathogen were 
considered to be one episode of BSI. One blood 
culture yielding two significant pathogens was 
considered to be two episodes caused by each 
pathogen. The onset of a BSI was defined as 
the day of the first positive blood culture. 
Gastrointestinal (GI) disturbance was defined 
as the clinical symptoms of diarrhea and 
paralytic ileus.
　Microbiology: Bloodstream isolates were 
identified at the species level with the VITEK 
system (from BIOMERIEUX) according to the 
manufacturer's instructions. The MICs were 
determined with frozen plates in accordance 
with the Clinical Laboratory Standards 
Institute (CLSI) guidelines11). MRSA was 
defined as Staphylococcus aureus that was 
resistant to oxacilin (MIC >4 μg/mL).
　Statistical analysis: Continuous variables 
were compared using the Mann-Whitney U 
test (non-normaly distributed variables). 
Categorical variables were evaluated using the 
chi-square or the two-tailed Fisher's Exact 
Test. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated to evaluate the 
strength of any association that emerged. 
Values are expressed as the means ± standard 
deviation (continuous variables) or as percent-
ages of the group from which they were 
derived (categorical variables). A P value of 
<0.05 was considered statisticaly significant. 
Multivariate analysis was used to identify 
independent risk factors for BSI patients and 
to analyze the specific features of critical BSIs. 
For this analysis, logistic regression was used, 
and variables were incorporated. Al statistical 
analyses were performed using the PASW 
software, version 17.0 for Windows.
RESULTS
　During the 5-year study period (2003 to 
2007), 255 hospitalized patients were enroled. 
They were newly diagnosed with hematological 
malignancies at the adult hematology ward. 
Their complete medical records were available 
for analysis.
Predisposing factors for BSI onset
　A total of 119 BSIs were identified in 67 of 
255 patients (incidence: 26.2%). The predispos-
ing factors for the BSI patients are presented 
in Table 1. On univariate analysis, diagnosis of 
acute leukemia (47.8% BSI patients vs. 9.6% 
non-BSI patients), a history of alogeneic 
hematopoietic stem cel transplantation (35.8% 
vs. 8.0%, respectively), a history of a central 
venous catheter (80.6% vs. 38.3%, respective-
ly), a complication of GI disturbance (37.3% vs. 
15.4%, respectively), duration of neutropenia 
(67.2% vs. 17.5%, respectively), and profound 
neutropenia (73.1% vs. 14.9%, respectively) 
were significantly more frequent in BSI 
patients than in non-BSI patients. On logistic 
regression analysis, performance status 4 
(P=0.014), GI disturbance (P=0.005), pro-
found neutropenia (ANC=0 cels/μL) (P= 
0.001) was the independent factors associated 
with BSI patients. The patients with profound 
neutropenia were treated with dose-intensity 
chemotherapy, such as remission-induction 
therapy for acute leukemia, salvage therapy for 
malignant lymphoma, and conditioning regi-
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mens for HSCT.
Mortality
　The BSI patients had a higher mortality (42 
of 67; 62.7%) than the non-BSI patients (63 of 
188; 33.5%). Of 67 BSI patients, 25 (37.7%) 
had a history of critical BSIs. The BSI patients 
without a history of critical BSIs also had a 
higher mortality (17 of 42; 40.5%) than the 
non-BSI patients. This rate may be explained 
by fungal and viral infections that are related 
to mortality in neutropenic patients, but are 
dificult to detect as BSIs. In fact, 15 of 42 BSI 
patients (35.7%) who died were suspected of 
having fungal infections with positive β-D-
glucan values, and 3 of 42 BSI patients (7.1%) 
had aspergilus pneumonia. Death caused by 
underlying disease was dificult to be distin-
guished from other causes, because many 
complications, such as infections, drug toxicity, 
chemotherapy-induced organ damage, and 
disease progression, were present when the 
　Table 1. Predisposing factors for BSI onset in 255 patients with hematological malignancies
No. (%) of 
P-value
(Multivariate)
P-value
(Univariate)
Non-BSI patients
n = 188
BSI patients
n = 67Factors
0.60 0.2862 ± 1656 ± 18Mean ± SD age (y) 
0.630.89102 (54.3)37 (55.2)Male sex
Diagnosis
0.10 <0.0118  (9.6)32 (47.8)Acute leukemia
0.250.01105 (55.8)22 (32.8)Malignant lymphoma
0.530.1141 (21.8)8 (11.9)Multiple myeloma
----24 (12.8)5  (7.5)Others
History of therapy
----167 (88.8)38 (56.7)Chemotherapy and others
0.990.266  (3.2)5  (7.5)Autologous HSCT*
0.86<0.0115  (8.0)24 (35.8)Alogeneic HSCT
0.010.2543 (22.9)20 (29.8)Performance status 4**
0.36<0.0172 (38.3)54 (80.6)History of CV* catheter
Complications
0.270.5525 (13.3)11 (16.4)Pneumonia
<0.01<0.0129 (15.4)25 (37.3)GI* disturbance
Duration of neutropenia***
0.31<0.0133 (17.5)45 (67.2)ANC* <500 cels/μl for > 7 days
Degree of neutropenia***
0.47<0.01103 (54.8)14 (20.9)0 < ANC < 1000 cels/μl
<0.01<0.0128 (14.9)49 (73.1)ANC = 0 cels/μl (profound)
----63 (33.5)42 (62.7)Mortality
　 *HSCT indicates hematopoietic stem cel transplantation; GI, gastrointestinal; CV, central venous; 
ANC, absolute neutrophil count.
 **Performance status 4 of the Eastern Cooperative Oncology Group criteria (ECOG) indicates 
bedridden status.
 ***Duration and degree of neutropenia were evaluated before BSI onset in BSI patients. In non-BSI 
patients, the most prolonged duration and the minimum ANC during admission were evaluated.
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patients with hematological malignancies died.
Predisposing factors for death caused 
by first BSI.
　Of 67 BSI patients, 13 (19.4%) died within 
21 days after the first BSI onset. In these 
patients, the main cause of death was 
considered to be the first BSI. Predisposing 
factors for death caused by the first BSI are 
presented in Table 2. Advanced age (69±9 y, 
non-survivors vs. 52±19 y, survivors), perform-
ance status 4 (92.3% vs. 14.8%, respectively), 
presence of pneumonia (38.5% vs. 11.1%, 
respectively), and presence of GI disturbance 
(76.9% vs. 27.8%, respectively) were signifi-
cantly more common in the non-survivors than 
in the survivors. On the other hand, the factors 
that were statisticaly significant predisposing 
factors for BSI onset (Table 1), such as 
diagnosis of acute leukemia, alogeneic HSCT, 
duration of neutropenia, and profound neutro-
penia, were not significantly diferent between 
non-survivors and survivors.
Species Distribution of Pathogens
　The species distribution of pathogens 
isolated in critical and non-critical BSIs was 
markedly diferent (Table 3). The common 
pathogens in critical BSIs were Enterococcus 
species (11 of 29; 37.9%), MRSA (5 of 29; 
17.2%), and Pseudomonas species (5 of 29; 
17.2%). CoNS were not isolated in critical 
BSIs, although they were most common in non-
critical BSIs (32 of 90; 35.6%). Similarly, 
Corynebacterium species, Streptococcus species, 
and Bacilus species were rare in critical BSIs 
but common in non-critical BSIs. With respect 
to fungal BSI, only 3 (3.3%) fungal BSIs caused 
by Candida parapsilosis were observed, and al 
of them were non-critical BSIs.
　The frequencies of pneumonia and GI 
disturbance with BSIs were: 14.3% and 64.3% 
in MRSA BSIs; 18.7% and 75.0% in Enterococ
cus BSIs; and 33.3% and 33.3%. in Pseudomo
nas BSIs.
Characteristics of Critical BSIs
　One of the clinical problems in patients with 
hematological malignancies was recurrence of 
BSI episodes during the course of cyclic 
chemotherapy and salvage therapy for relapse 
of disease. Therefore, the number of BSI 
　Table 2. Predisposing factors for death caused by first BSI in 67 BSI patients
No. (%) of BSI patients
P-value
(Univariate)
Survivors
(n = 54)
Non-survivors
(n = 13)Factor
<0.0152 ± 1969 ± 9Mean ± SD age (y) 
0.5431 (57.4)6 (46.2)Male sex
0.5427 (50.0)5 (38.5)Diagnosis of acute leukemia
0.7141 (75.9)11 (84.6)No remission of the underlying disease
0.1122 (40.7)2 (15.3)Alogeneic HSCT
<0.018 (14.8)12 (92.3)Performance status 4
1.0042 (77.8)10 (76.9)Presence of CV catheter
0.036 (11.1)5 (38.5)Presence of pneumonia
<0.0115 (27.8)10 (76.9)Presence of GI disturbance
0.5423 (42.6)7 (53.8)ANC < 500 cels/μl for > 7 days
0.0942 (77.8)7 (53.8)Profound neutropenia (ANC = 0 cels/μl)
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episodes in each patient varied from 1 to 7 
episodes (41 patients with 1 episode, 10 
patients with 2 episodes, 10 patients with 3 
episodes, 4 patients with 4 episodes, 1 patient 
with 5 episodes, 1 patient with 7 episodes). To 
examine the characteristics of critical and non-
critical BSI episodes, the factors were classified 
into three categories: patient-related factors, 
treatment-related factors, and pathogen-re-
lated factors (Table 4). For patient-related 
factors, performance status 4 (82.8% of critical 
BSI episodes vs. 12.2% of non-critical BSI 
episodes), presence of pneumonia (27.6% vs. 
6.7%, respectively), and presence of GI 
disturbance (69.0% vs. 31.1%, respectively) 
were significantly diferent between critical 
and non-critical BSI episodes. For treatment-
related factors, fluoroquinolone prophylaxis, 
prior exposure to antimicrobial therapy, and 
empirical therapy did not difer significantly 
between critical and non-critical BSI episodes. 
For pathogen-related factors, Enterococcus 
species as the pathogen was significantly more 
common (37.9% vs. 5.6%, respectively) in 
critical BSIs than in non-critical BSI episodes. 
On logistic regression analysis, performance 
status 4 (OR=20.1; 95% CI=4.4 to 91.0; 
P<0.001) was the independent factor most 
associated with critical BSI episodes.
 Table 3. Species distribution of pathogens isolated in critical and non-critical BSIs
No. (%) of BSIs
Total
n = 119
Non-critical
n = 90
Critical
n = 29Pathogen
89 (74.8)69 (76.7)20 (69.0)Gram-positive organisms, al
Staphylococcus species
32 (26.9)32 (35.6)0CoNS*
3 (2.5)1  (1.1)2  (6.9)MSSA**
14 (11.7)9 (10.0)5 (17.2)MRSA***
Enterococcus species
12 (10.1)3  (3.3)9 (31.0)Enterococcus faecalis
3  (2.5)2  (2.2)1  (3.4)Enterococcus faecium
1  (0.8)01  (3.4)Enterococcus galinarum
9  (7.5)8  (8.9)1  (3.4)Corynebacterium species
8  (6.7)8  (8.9)0Streptococcus species
7  (5.9)6  (6.7)1  (3.4)Bacilus species
27 (22.7)18 (20.0)9 (31.0)Gram-negative organisms, al
9  (7.5)4  (4.4)5 (17.2)Pseudomonas species
Other Gram-negative species
5  (4.2)5  (5.6)0Escherichia coli
4  (3.3)3  (3.3)1  (3.4)Enterobacter cloacae
3  (2.5)1  (1.1)2  (6.9)Stenotrophomonas maltophilia
3  (2.5)2  (2.2)1  (3.4)Klebsiela pneumoniae
2  (1.7)2  (2.2)0     Aeromonas hydrophila
1  (0.8)1  (1.1)0     Acinetobacter anitratus
3  (2.5)3  (3.3)0     　Fungi　Candida parapsilosis
*CoNS indicates coagulase-negative staphylococci;**MSSA, methicilin-sensitive staphylococcus 
aureus; ***MRSA, methicilin-resistant staphylococcus aureus. 
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Susceptibility Patterns of BSI Pathogens
　The susceptibility patterns of major BSI 
pathogens are presented in Table 5, but only 
antibiotics tested in al strains of each 
pathogen  are  shown.  Previous  studies19) 
showed the close association between the use 
of antibiotics and the emergence of antibiotic 
resistance. Resistance to cefozopran, which we 
often used empiricaly, was seen in 57% of 
MRSAs, 94% of Enterococcus species, 33% of 
Corynebacterium species, and 28% of Bacilus 
species. Resistance to levofloxacin, which we 
often used prophylacticaly, was observed in 
69% of CoNSs, 93% of MRSAs, 88% of 
Enterococcus species, 44% of Corynebacterium 
species, 25% of Streptococcus species, 43% of 
Bacilus species, and 33% of Pseudomonas 
species. Most pathogens tested were sensitive 
to vancomycin, but two strains of Streptococcus 
species isolated from 2 patients were resistant. 
One of these patients had acute myelogenous 
leukemia (AML) and had prior exposure to 
vancomycin in our ward. Another patient with 
myelodysplastic syndrome (MDS) had four 
admissions to another hospital, and the 
medical  records  were  not  available  for 
determining whether vancomycin had been 
used.
DISCUSSION
　Strategies to minimize inefective antimicro-
bial therapy for BSI have been identified by 
practice guidelines5), 20). In addition, clinicians 
　Table 4. Characteristics of critical and non-critical BSI episodes
No. (%) of BSIs
P-value
(Multivariate)
P-value
(Univariate)
Non-critical
n = 90
Critical
n = 29 Characteristic at BSI onset
Patient-related factors
0.960.5868 (75.6)24 (82.8)No remission of the underlying disease
<0.01<0.0111 (12.2)24 (82.8)Performance status 4
0.790.8839 (43.3)13 (44.8)ANC <500 cels/μl for > 7 days
0.350.7273 (81.1)25 (86.2)Presence of CV catheter
0.20<0.016  (6.7)8 (27.6)Presence of pneumonia
0.17<0.0128 (31.1)20 (69.0)Presence of GI disturbance
Treatment-related factors
0.120.9671 (78.9)23 (79.3)Fluoroquinolone prophylaxis
Prior exposure to antimicrobial therapy
0.350.1843 (47.8)18 (62.1)　　Cephalosporins
0.400.3421 (23.3)10 (34.5)　　Carbapenems
----40 (44.4)5 (17.2)　　None
Empirical therapy
0.260.5033 (36.7)8 (27.6)　　Cephalosporins
0.660.5315 (16.7)7 (24.1)　　Carbapenems
0.211.0030 (33.3)10 (34.5)　　Aminoglycoside plus　　　　other antimicrobial agents
Pathogen-related factors
0.190.479 (10.0)5 (17.2)MRSA
0.09<0.015  (5.6)11 (37.9)Enterococcus species
0.230.064  (4.4)5 (17.2)Pseudomonas species
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can improve the therapy for BSI by using 
empirical antimicrobial therapy based on 
individual patient characteristics and the 
prevailing pathogens and their antimicrobial 
susceptibility profiles in their hospitals. In this 
study, among patients with hematological 
malignancies, the predisposing factors for BSI 
onsets, predisposing factors for death caused 
by BSI, species distribution of pathogens with 
susceptibility patterns, and characteristics of 
critical BSI episodes were identified.
　Patients with hematological malignancies 
are at high-risk for BSI due to chemotherapy-
induced neutropenia. The attack rate of BSI in 
neutropenic patients is high (11%-38%)12)-15). In 
our study, 76.0% (194 of 255) of patients had 
histories of neutropenia, and BSI occurred in 
32.5% (63 of 194) of these patients; this rate 
was consistent with previous reports.
　Neutropenia is the strongest risk factor for 
infection21), and bacteremia usualy develops 
when  ANC  fals  to  <100  cels/μL22), 23). 
Furthermore, we have often observed that BSI 
improves rapidly after the appearance of 
neutrophils in peripheral blood at the end of 
myelosuppression, albeit at ANC <100 cels/ 
μL. Therefore, we distinguished profound 
neutropenia with ANC=0 cels/μL from 
neutropenia with 0<ANC<1000 cels/μL for 
the analysis．In 30.1% (77 of 255) of patients, 
the minimum ANC decreased to the level of 
ANC=0 cels/μL before BSI onset in BSI 
patients and during admission in non-BSI 
patients. On multivariate analysis, a history of 
profound neutropenia was strongly associated 
with BSI. In contrast, neutropenia with 
0<ANC<1000 cels/μL was significantly less 
common in BSI patients than in non-BSI 
patients. These results suggest that the risk of 
BSI onset markedly increased with the absence 
of neutrophils in the peripheral blood.
　BSIs are recognized to have high mortality 
rates. However, mortality studies vary in both 
measures and populations16). Wisplinghof et 
al. reported that the overal mortality rate in 
BSI patients with hematological malignancies 
and solid neoplasms was 32%1). In the present 
study, the mortality rate (62.7%) of the BSI 
patients  was  two-fold  higher  than  the 
previously reported rate, presumably because 
　Table 5. Susceptibility patterns of BSI pathogens
Percentage (%) of resistance to tested antibiotics
 Pathogen (no. of strains)
VCMLVFXIPMCZOPAMP
069160--CoNS (32)
0936457--MRSA (14)
088--9419Enterococcus species (16) 
044--3344Corynebacterium species (9)
2525--00Streptococcus species (8)
043--2814Bacilus species (7)
--333311--Pseudomonas species (9)
AMP indicates ampicilin (resistant, > 16); CZOP, cefozopran (resistant, > 32); IPM, imipenem 
(resistant, >16);  LVFX, levofloxacin (resistant, >8; >4 in staphylococcal BSIs); VCM, vancomycin 
(resistant, >16).
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of other factors that afect mortality, such as 
fungal infection, chemotherapy toxicity, and 
underlying disease progression. On the other 
hand, 19.4% (13 of 67) of BSI patients died 
within 21 days after the first BSI onset.
　In the analysis of predisposing factors for 
death caused by first BSI, performance status 
4, presence of pneumonia, and presence of GI 
disturbance were significantly more common 
in non-survivors than in survivors. Thus, 
performance status 4 and GI disturbance were 
associated with not only BSI onset but also 
death caused by BSI. However, profound 
neutropenia was not significantly diferent 
between non-survivors and survivors, even 
though which is the major predictor for BSI 
onset.  These  results  might  reflect  the 
pathophysiological diference between BSI 
onset and recovery from BSI. Poor perform-
ance status, GI disturbance and profound 
neutropenia permit the pathogens to invade 
into the body and proliferate, resulting in onset 
of BSIs. Furthermore, it is thought that the 
patients with poor performance status and 
severe complications were dificult to keep 
their general conditions until the recovery of 
bone marrow functions.
　To make further investigations of character-
istics of BSIs associated with death, we 
distinguished critical BSI episodes from non-
critical BSI episodes and compared the 
characteristics of each BSI episodes. For 
patient-related factors, performance status 4, 
presence of pneumonia, and presence of GI 
disturbance were significantly diferent be-
tween critical and non-critical BSI episodes. 
This result was consistent with the result of 
the analysis of predictors for death caused by 
BSI, and moreover, performance status 4 was 
the independent factor most associated with 
critical BSI episodes on multivariate analysis. 
On the other hand, the percentage of no 
remission of the underlying disease was not 
significantly diferent between critical and non-
critical BSI episodes. For this reason, we could 
not take into account the achievement of 
remission when we determined the underlying 
disease status at BSI onset. In fact, most 
patients  with  non-critical  BSIs  achieved 
remission of underlying disease despite sho-
wing no remission at BSI onset.
　With respect to treatment-related factors, 
82.8% of critical BSI episodes occurred in 
patients with prior exposure to antimicrobial 
therapy in our ward. In addition, Enterococcus 
species, MRSA, and Pseudomonas species 
(common pathogens in critical BSIs) were 
partialy resistant to cefozopran, which we 
often used empiricaly, and levofloxacin, which 
we used for prophylaxis. These findings 
suggest that multidrug-resistant organisms 
produced by exposure to broad-spectrum 
antibiotics selectively remained and may have 
led to critical BSIs.
　For pathogen-related factors, Enterococcus 
species were the most common pathogens in 
critical BSIs, and 75.0% (12 of 16) of BSI 
caused by Enterococcus species folowed GI 
disturbances. These findings suggest that 
Enterococcus species translocate to the blood-
stream folowing chemotherapy-induced GI 
disturbances and cause critical BSIs. This 
hypothesis is generaly consistent with previ-
ous reports. Cabalero et al. reported that the 
mortality rate of patients with cases of 
enterococcal bacteremia was high, although it 
has often been related to a patient's underlying 
conditions rather than to the infection itself17). 
To prevent enterococcal BSIs, the barrier 
function of the bowel mucosa should be 
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maintained. In general, the depletion of 
nutrients in the bowel lumen is accompanied 
by  degenerative  changes  in  the  bowel 
mucosa18). Thus, appropriate nutritional sup-
port may prevent enterococcal BSIs and 
improve patients' outcomes.
　Al 16 Enterococcus strains tested were 
vancomycin-sensitive.  Four  patients  with 
enterococal BSI were given vancomycin after 
BSI onset, but al of these patients died 
without recovery of marrow function due to 
progression of underlying disease. Widespread 
empirical use of vancomycin for suspected 
enterococcal BSI in patients with severe 
underlying conditions is undesirable, since 
overuse might facilitate the emergence of 
vancomycin-resistant  Enterococcus  strains. 
Assessment of the predictive factors identified 
in this study might help to avoid the overuse of 
antibiotics.
　Our study had two limitations that must be 
acknowledged. First, our analysis was retro-
spective, and it was performed at a single 
center; thus, the results are not necessarily 
applicable to other settings. Second, our results 
were based on the findings of only a few cases; 
therefore, it is unclear whether studies with a 
large number of cases would lead to the same 
conclusions.
　In conclusion, the local profiles of BSIs 
identified are useful for choosing risk-based 
empirical antimicrobial therapy in our ward. 
Furthermore, BSIs associated with death occur 
in patients with severe underlying conditions, 
so that non-antimicrobial supportive therapy 
needs to be implemented to improve BSI 
patients' survival. The results of this study 
invite investigations of efective non-antimicro-
bial supportive therapy.
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